CMBA
CSTL icon

C.M. Bidwell & Associates’s Castle Biosciences CSTL Stock Holding History

C.M. Bidwell & Associates’s Portfolio CSTL Stock Details CSTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-3,180
Closed -$63.7K – 463
2025
Q1 		$63.7K Buy
3,180
+482
+18% +$11.9K 0.04% 200
2024
Q4 		$71.9K Buy
2,698
+98
+4% +$2.98K 0.04% 204
2024
Q3 		$74.2K Buy
2,600
+945
+57% +$24.1K 0.05% 200
2024
Q2 		$36K Buy
+1,655
New +$36.9K 0.02% 245
2023
Q2 		– Sell
-75
Closed -$1.7K – 534
2023
Q1 		$1.7K Buy
+75
New +$1.83K ﹤0.01% 482
2021
Q2 		– Sell
-265
Closed -$18K – 578
2021
Q1 		$18K Sell
265
-70
-21% -$5.26K 0.01% 356
2020
Q4 		$22K Sell
335
-7,000
-95% -$379K 0.02% 332
2020
Q3 		$377K Sell
7,335
-230
-3% -$10.2K 0.35% 41
2020
Q2 		$285K Sell
7,565
-1,270
-14% -$43.4K 0.26% 85
2020
Q1 		$263K Buy
8,835
+6,685
+311% +$202K 0.28% 95
2019
Q4 		$74K Buy
+2,150
New +$52.6K 0.07% 179

Other funds holding CSTL

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
Allianz Asset Management
Allianz Asset Management Munich, Germany $95.4B AUM 38.74% 1-Year Est. Return

C.M. Bidwell & Associates's CSTL Position: Q2 2025 in Review

C.M. Bidwell & Associates sold out of Castle Biosciences (CSTL) in Q2 2025, closing a stake of 3,180 shares — an estimated $63.7K sold.

C.M. Bidwell & Associates first reported a position in CSTL in Q4 2019 and held it in 11 quarters. The position peaked at $377K in Q3 2020. 152 funds tracked by Wall St. Rank hold CSTL as of Q2 2025.

  • C.M. Bidwell & Associates reported no remaining Castle Biosciences position as of Q2 2025 after selling out during the quarter.
  • C.M. Bidwell & Associates sold 3,180 Castle Biosciences shares in Q2 2025, an estimated $63.7K.
  • C.M. Bidwell & Associates first reported a position in Castle Biosciences in Q4 2019 and held it in 11 quarters.
  • C.M. Bidwell & Associates's Castle Biosciences position peaked at $377K in Q3 2020.
  • 152 funds tracked by Wall St. Rank held Castle Biosciences as of Q2 2025.

Based on C.M. Bidwell & Associates's 13F filing for Q2 2025, filed 14 Aug 2025.